Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder

BACKGROUND: Social anxiety disorder (SAD) is associated with substantial reduction in health-related quality of life (HRQoL). Escitalopram has proven efficacy in the short-term treatment of SAD and prevention of relapse. OBJECTIVES: To determine whether the clinical effects of treatment translated i...

Descripción completa

Detalles Bibliográficos
Autores principales: François, C, Montgomery, S A, Despiegel, N, Aballéa, S, Roïz, J, Auquier, P
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704928/
https://www.ncbi.nlm.nih.gov/pubmed/18759783
http://dx.doi.org/10.1111/j.1742-1241.2008.01879.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704928/
https://www.ncbi.nlm.nih.gov/pubmed/18759783
http://dx.doi.org/10.1111/j.1742-1241.2008.01879.x

Ejemplares similares